|
Analysis of HER2 mutant bladder urothelial carcinomas reveals unique mutational signature. |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Consulting or Advisory Role - Revolution Medicines |
Patents, Royalties, Other Intellectual Property - Receive periodic royalties related to T790M patent awarded to Memorial Sloan Kettering Cancer Center |
|
|
Employment - Foundation Medicine; Foundation Medicine |
|
Stock and Other Ownership Interests - Agios; Blueprint Medicines; Exelixis; Genocea Biosciences |
Patents, Royalties, Other Intellectual Property - patents via FOundation Medicine; Patents via Seres Health on microbiome stuff in non neoplastic disease (I) |
|
|
Employment - Foundation Medicine |
Leadership - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
Speakers' Bureau - Foundation Medicine |
Research Funding - Foundation Medicine |
Patents, Royalties, Other Intellectual Property - Foundation Medicine |
Travel, Accommodations, Expenses - Foundation Medicine |